Community Clinical Research, Inc.

Austin, Texas 78756

3 studies enrolling now · 59 studies all time

What they study most

Acute Mania, Acute Schizophrenia, Alzheimer Disease, Bipolar 1 Disorder, Bipolar Disorder, Bipolar I Disorder, Cannabis Withdrawal, Cognitive Dysfunction, Depression, Depressive Disorder, Major, Depressive Episodes, Bipolar I Depression, Epilepsy

Studies at this site

• Efficacy of PP-01 in Mitigating Cannabis Withdrawal Symptoms in Adults With Cannabis Use Disorder — Recruiting now
• A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia — Recruiting now
• A Study of the Feasibility, Safety and Tolerability of Aticaprant as Adjunctive Treatment in Participants With Schizophrenia — Recruiting now
• Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Bipolar I Disorder — Recruiting now
• A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia — Completed
• A Study to Test Long-term Safety of Iclepertin in People With Schizophrenia Who Took Part in a Previous CONNEX Study — Stopped early
• Study to Evaluate Efficacy and Safety of Ropanicant in MDD Patients — Completed
• A Trial of the Safety and Efficacy of SEP-363856 in the Treatment of Adults With Major Depressive Disorder — Completed
• BHV-7000 Acute Treatment of Bipolar Mania — Completed
• BHV-7000 Open-Label Extension Bipolar Mania Study — Stopped early
• Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-1) — Completed
• This Study Tests Whether BI 409306 Prevents Patients With a Specific Type of Mental Illness (Attenuated Psychosis Syndrome) From Becoming Worse. This Study Looks at How Well Patients Tolerate the Medicine and How Effective it is Over 1 Year — Stopped early
• This Study Tests Whether BI 409306 Prevents Patients With Schizophrenia From Becoming Worse. This Study Looks at How Well Patients Tolerate BI 409306 and How Effective it is Over 6 Months — Stopped early
• A Clinical Trial to Determine the Long-term Safety and Tolerability of an Investigational Drug in People With Major Depressive Episode Associated With Bipolar I Disorder (Bipolar I Depression). — Stopped early
• A Study to Assess Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adult Patients With Schizophrenia (EMERGENT-3) — Completed
• A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication — Completed
• Study to Evaluate the Pharmacokinetics (PK) and Safety/Tolerability of Long-Acting Oral LYN-005 — Completed
• A Clinical Study of an Investigational Drug for the Treatment of Major Depressive Episode Associated With Bipolar I Disorder. — Stopped early
• Study of Systemic and Ocular Safety and Pharmacokinetics of BI 409306 in Patients With Schizophrenia, Alzheimer's Disease, and Healthy Volunteers — Completed
• A Study to Evaluate 3 Dose Levels of Luvadaxistat of Adults With Negative Symptoms of Schizophrenia — Completed
• A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-692 as an Adjunctive Treatment in Adults With Schizophrenia — Completed
• A Trial of the Efficacy and the Safety of RO6889450 (Ralmitaront) vs Placebo in Patients With an Acute Exacerbation of Schizophrenia or Schizoaffective Disorder — Completed
• A Multiple Dose Study to Assess the Safety, Tolerability and PK of Risperidone Extended Release Capsules — Completed
• Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in a Dose-Reduction Paradigm in the Prevention of Relapse in Participants With Schizophrenia — Stopped early
• Study to Evaluate the Efficacy and Safety of Risperidone in Situ Microparticle (ISM)® in Patients With Acute Schizophrenia — Completed
• A Trial in Adult Participants With Schizophrenia Treated Prospectively for 6-months With Abilify MyCite® — Stopped early
• Efficacy, Safety, and Tolerability of SPD489 in Adults With Schizophrenia and Predominant Negative Symptoms — Completed
• A Study to Assess Safety and Efficacy of KarXT in Adult Patients With Schizophrenia — Completed
• A Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Participants With Bipolar I Disorder. — Completed
• Long-term Safety Study of Rapastinel as Adjunctive Therapy in Patients With Major Depressive Disorder — Completed
• A Study of Rapastinel as Adjunctive Therapy in the Prevention of Relapse in Patients With Major Depressive Disorder — Completed
• A Trial to Assess Brexpiprazole Versus Placebo for the Treatment of Acute Manic Episodes Associated With Bipolar I Disorder — Completed
• A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-02) — Completed
• A Twelve Week, Open Label Extension Study in Patients With Schizophrenia — Completed
• Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Prior to First Dose of VIVITROL® (Naltrexone for Extended-Release Injectable Suspension) — Completed
• Randomized, Double-blind, Placebo Controlled, Multi-center and Tolerability of RBP-7000 in Schizophrenia Patients — Completed
• Long Term Study of RBP 7000 in the Treatment of Subjects With Schizophrenia — Completed
• Study to Determine the Pharmacokinetics, Safety & Tolerability of Aripiprazole in Adults With Schizophrenia — Completed
• Crossover Bioequivalence Study of Quetiapine Fumarate 300 mg Tablets Under Steady State Fasted Conditions — Completed
• A Study to Investigate the Efficacy, Safety and Tolerability of Four Different Doses of BI 409306 Compared to Placebo Given for 12 Weeks in Patients With Schizophrenia on Stable Antipsychotic Treatment. — Completed
• A Study to Evaluate Efficacy and Safety of Bitopertin in Participants With Persistent, Predominant Negative Symptoms of Schizophrenia — Completed
• Safety & Efficacy of Eslicarbazepine Monotherapy in Sub.w/Partial Epilepsy Not Well Controlled by Current Antiepileptic — Completed
• An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia — Stopped early
• PEARL Schizophrenia Maintenance — Completed
• Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder — Completed
• Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression — Stopped early
• Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression — Completed
• Safety and Tolerability Study of Aripiprazole IM Depot in Adult Subjects With Schizophrenia — Completed
• Lurasidone HCl - A Long Term Safety Phase 3 Study of Patients With Clinically Stable Schizophrenia — Completed
• An Randomized Open-Label PK Study of LY03004 Compared to Risperdal® Consta® in Stable Patients With Schizophrenia or Schizoaffective Disorder — Completed